Letermovir for R+ Study

Starting soon · Phase 4

Conditions studied: Kidney Transplant, Liver Transplant

In brief

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.

Key facts

Study ID

NCT07706166

Run by

University of Wisconsin, Madison

People needed

146

Starts

2026-08-01

Expected to finish

2029-08-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
• Adults who received a kidney transplant, liver transplant, or any combination thereof

You may not qualify if…

• Known contraindication to letermovir or its excipients
• Current participation in another CMV related study
• Unwilling or unable to participate in the study protocol

Where it is running

• University of Wisconsin - Madison — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.